日本汉方医学整合管理对轻中度COVID-19症状缓解及重症预防的多中心随机对照试验方案摘要
本研究为多中心、干预性、平行组、1:1随机、研究者发起的双臂试验,纳入8家日本医院的轻中度COVID-19患者,比较常规治疗联合葛根汤与柴胡桂枝汤加桔梗石膏(KT+SSKKS)与单纯常规治疗在14天内症状改善和重症预防方面的效果。主要终点为至少一种症状改善所需天数,计划随机150例。
要点
- 葛根汤与柴胡桂枝汤加桔梗石膏联合常规治疗用于轻中度COVID-19症状缓解。
- 主要终点为14天内至少一种症状(发热、咳嗽、咳痰、乏力、气短)改善的天数。
- 采用最小化法随机,按疾病严重程度和年龄(<65、65-<75、≥75岁)平衡组间。
核心结论
- 假设在常规治疗基础上加用KT和SSKKS能更有效缓解轻中度COVID-19患者症状并预防重症。
研究设计与样本
- 多中心、干预性、平行组、1:1随机、研究者发起的双臂研究,从8家日本学术和非学术医院招募门诊和住院患者。
- 纳入标准:SARS-CoV-2阳性、轻中度COVID-19、有症状、≥20岁、能日语沟通、签署知情同意。
- 排除标准包括痴呆或精神症状无法知情同意、对汉方或西药过敏、妊娠哺乳、无法随访、参与其他试验、低钾血症或口服呋塞米/类固醇等。
- 随机采用最小化法,按疾病严重程度和年龄(<65、65-<75、≥75岁)平衡,使用计算机生成随机数,开放标签。
- 计划随机150例(汉方组75例,对照组75例),以补偿失访。
主要发现
- 主要终点为治疗最初14天内至少一种症状(发热、咳嗽、咳痰、乏力、气短)改善所需天数。
- 咳嗽、咳痰、乏力和气短采用数字评定量表,改善定义为从治疗开始至少连续2天评分下降2分。
- 发热改善定义为体温低于37°C。
- 样本量基于汉方组中位生存时间估计为3天、对照组为1.5倍,单侧显著性水平5%、把握度70%、1:1分配,计算需126例。
关键数值与推荐
- 汉方组:葛根汤(TJ-1,TSUMURA)2.5g和柴胡桂枝汤加桔梗石膏(TJ-109,TSUMURA)2.5g,每日3次口服,共14天,联合常规治疗。
- 对照组:仅常规治疗,包括解热镇痛药或止咳药用于感染后出现的症状。
临床怎么用
- 该方案为轻中度COVID-19患者提供了在常规治疗基础上加用汉方药的随机对照试验设计。
- 主要终点采用症状改善天数,结合数字评定量表和体温阈值定义改善。
局限性
- 开放标签设计,未设盲。
- 样本量基于既往汉方药对COVID-19和H1N1流感患者疗效的研究估算。
- 试验状态为方案版本1.2(2020年8月20日),预计招募期为2020年10月1日至2023年10月31日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to test our hypothesis that additional administration of traditional Japanese (Kampo) medicine, kakkonto (kakkon-to: KT) and shosaikotokakikyosekko (sho-saiko-to-ka-kikyo-sekko: SSKKS), is more effective in relieving symptoms and preventing the onset of severe infection in mild-to-moderate COVID-19 patients compared to those treated only with conventional treatment. TRIAL DESIGN: The study is designed as a multi-center, interventional, parallel-group, randomized (1:1 ratio), investigator-sponsored, two-arm study. PARTICIPANTS: Patients and inpatients will be recruited from 8 Japanese academic and non-academic hospitals. The inclusion and exclusion criteria are as follows: Inclusion criteria: 1. Diagnosed as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 2. Clinical stages of mild-to-moderate COVID-19 3. Symptomatic 4. ≥ 20 years of age 5. Male or female 6. Ability to communicate in Japanese 7. Outpatients and inpatients 8. Provided informed consent Exclusion criteria: 1. Difficulty in providing informed consent due to dementia, psychosis, or psychiatric symptoms 2. Allergic to Kampo or Western medicines used in this study 3. Pregnant and lactating 4. Unable to follow up 5. Participating in another clinical trial or interventional study 6. Hypokalemic or taking oral furosemide or steroids 7. Determined unsuitable for this study by the physician INTERVENTION AND COMPARATOR: Patients in the control group will receive conventional treatment with antipyretics, painkillers, or antitussives for symptoms that occurred after they contracted the SARS-CoV-2 infection. Patients in the Kampo group will receive 2.5 g of KT (TJ-1@TSUMURA and Co.) and 2.5 g of SSKKS (TJ-109@TSUMURA and Co.) 3 times a day, orally, for 14 days in addition to the conventional treatment as mentioned above. MAIN OUTCOMES: The number of days till at least one of the symptoms (fever, cough, sputum, malaise, shortness of breath) improves in the first 14 days of treatment. To assess the cough, sputum, malaise, and shortness of breath, a numeric rating scale will be used to define improvement in terms of a 2-point decrease in the number of days from the start of treatment for at least 2 days. Fever will be defined as an improvement when the temperature is less than 37 °C. RANDOMIZATION: Patients are randomized (1:1 ratio) to each group using the minimization method, with balancing of the arms with severity of disease stage and patient age (< 65, 65 to < 75, or ≥ 75 years). Computer-generated random numbers will be used for the minimization method. BLINDING (MASKING): Open-label with no blinding NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The main research hypothesis of this study is that the combination of Kampo medicine and conventional treatment will significantly improve the patients' symptoms (fever, fatigue, cough, sputum, and shortness of breath) during the first 14 days of treatment as compared with conventional treatment alone. Concerning the analysis of the primary endpoint, the duration of time before improvement of at least one of the common cold-like symptoms (fever, malaise, cough, sputum, and shortness of breath) will be estimated using the Kaplan-Meier method, and the survival curves will be compared between groups using the log-rank test. Assuming this method of analysis and based on previous studies reporting the efficacy of Kampo medicine for COVID-19 and H1N1 influenza patients, the median survival time in the Kampo medicine group is estimated as 3 days; this time will be 1.5 times longer in the control group. Assuming a one-sided significance level of 5%, a power of 70%, and an allocation ratio of 1:1, the required sample size is calculated as 126 cases. To compensate for a loss in follow-up, we plan to include 150 cases in both groups (Kampo group = 75, control group = 75). TRIAL STATUS: Protocol version 1.2 as of August 20, 2020 Recruitment start (expected): October 1, 2020 Recruitment finish (expected): October 31, 2023 TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) jRCTs021200020 . Registered on August 25, 2020 FULL PROTOCOL: The full protocol is attached as an additional file and is accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Takayama S, Namiki T, Ito T, et al. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33008479. doi:10.1186/s13063-020-04746-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。